📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial (2024)

First Author: Goodyear C

Attributed to: PITCH2 - Protective Immunity through T Cells in Healthcare workers 2 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2665-9913(24)00065-1

Publication URI: http://dx.doi.org/10.1016/s2665-9913(24)00065-1

Type: Journal Article/Review

Parent Publication: The Lancet Rheumatology

Issue: 6

ISSN: 26659913